S. Chowdhury

2.0k citations

58 papers · 951 indexed · h-index 16

Pulmonary and Respiratory Medicine top 5%
- Prostate Cancer Treatment and Research 34
- Renal cell carcinoma treatment 11
Cancer Research top 10%
- Cancer, Lipids, and Metabolism 12
- Cancer Genomics and Diagnostics 5
Radiology, Nuclear Medicine and Imaging top 5%
- Radiopharmaceutical Chemistry and Applications 20
Oncology top 10%
- Cancer Treatment and Pharmacology 8
- PARP inhibition in cancer therapy 6
Hematology top 10%
Molecular Biology
- Renal and related cancers 6

Co-authors: Johann S. de Bono Gerhardt Attard Roberta Ferraldeschi Aurelius Omlin Andrea Zivi Alejo Rodríguez‐Vida David Lorente Diletta Bianchini
Cited by: Pulmonary and Respiratory Medicine Cancer Research Radiology, Nuclear Medicine and Imaging
Journals: Annals of Oncology (35 papers)Journal of Clinical Oncology (4 papers)British Journal of Cancer (2 papers)
Partner nations: United Kingdom United States France

In The Last Decade

S. Chowdhury

55 papers receiving 931 citations

Peers

Countries citing papers authored by S. Chowdhury

Since Specialization

Citations

This map shows the geographic impact of S. Chowdhury's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Chowdhury with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Chowdhury more than expected).

Fields of papers citing papers by S. Chowdhury

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Chowdhury. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Chowdhury. The network helps show where S. Chowdhury may publish in the future.

Co-authorship network

The 25 scholars most cited alongside S. Chowdhury, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with S. Chowdhury Line = papers co-authored together S. Chowdhury links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	1786P Effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in TITAN patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT) Annals of Oncology ·Axel S. Merseburger,Neeraj Agarwal,Anders Bjartell,Hiroji Uemura,広明田中,Amitabha Bhaumik,Juergen Boehm,Nguyen Toan Tran,Jong Won Lim,А. В. Чернявський,Suneel Mundle,И. А. Усенко,Shane McCarthy,K.N. Chi,S. Chowdhury	2023	2
2	1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304) Annals of Oncology ·Lisa G. Horvath,Ian D. Davis,Andrew Martin,拓斗林,Alastair Thomson,Thean Hsiang Tan,Shahneen Sandhu,M. Neil Reaume,David Pook,Francis Parnis,Scott North,Gavin Marx,John A. McCaffrey,Ray McDermott,Nicola Jane Lawrence,Mark Frydenberg,S. Chowdhury,K.N. Chi,Martin R. Stockler,Christopher J. Sweeney	2023	2
3	Symptoms and Prevalence of Constipation among Adult Population of Bangladesh Euroasian Journal of Hepato-Gastroenterology ·Dilip Kumar Ghosh,George Rouse,E Atkins,Wouter Huysse,K. Sri Varshini,S. Chowdhury,A. Lennarz	2023	1
4	Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer Annals of Oncology ·S. Chowdhury,Anders Bjartell,Neeraj Agarwal,Byung Ha Chung,Robert Given,Andrea Juliana Gomes,Axel S. Merseburger,Mustafa Özgüroğlu,Álvaro Juárez Soto,Hirotsugu Uemura,Maria Eduarda Melati,Sabine Brookman‐May,Anil Londhe,Amitabha Bhaumik,Suneel Mundle,Julie S. Larsen,Sharon McCarthy,K.N. Chi	2023	59
5	LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol Annals of Oncology ·Gerhardt Attard,Louise Brown,Nigel Clarke,Laura Murphy,William Cross,Robert H. Jones,Silke Gillessen,John M. Russell,Adrian Cook,Julie Bowen,Anna Lydon,Ian Pedley,Omi Parikh,S. Chowdhury,Zafar Malik,David Matheson,Chris Parker,Matthew R. Sydes,Max Parmar,Nicholas D. James	2021	5
6	659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2 Annals of Oncology ·S. Chowdhury,Akash Patnaik,David Campbell,Jeremy Shapiro,Alan H. Bryce,Ray McDermott,Brieuc Sautois,Nicholas J. Vogelzang,Richard Bambury,Éric Voog,Jie Zhang,Michelle Green,C. Corinna,Darrin Despain,Andrew D. Simmons,Simon P. Watkins,배원호,Jim Xiao,Wassim Abida	2020	2
7	611O Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) Annals of Oncology ·Nicholas D. James,Hannah Rush,Noel W. Clarke,Gerhardt Attard,Adrian Cook,David P. Dearnaley,Fazil Khurum,Alex Hoyle,Robert J. Jones,R. Millman,Alison Birtle,S. Chowdhury,Joanna Gale,Zafar Malik,Joe M. O’Sullivan,Evelina L. Fortajada,Denise Sheehan,Jacob Tanguay,Mahesh Parmar,Matthew R. Sydes	2020	14
8	Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer Annals of Oncology ·Eric J. Small,Fred Saad,S. Chowdhury,Stéphane Oudard,Boris Hadaschik,Julie N. Graff,David Olmos,Paul N. Mainwaring,Ahmed Muhammad Al-Zubi,Hiroji Uemura,Peter De Porre,Alexis K. Smith,강문상,Angela Lopez‐Gitlitz,Matthew R. Smith	2019	99
9	Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE Annals of Oncology ·Chris Parker,Nicholas D. James,Chris Brawley,Noel W. Clarke,Gerhardt Attard,S. Chowdhury,William Cross,David P. Dearnaley,Clare Gilson,Robert J. Jones,Malcolm D. Mason,R. Millman,Silke Gillessen,Chinnamani Eswar,Joanna Gale,J.F. Lester,Denise Sheehan,Anna Tran,Mahesh Parmar,Matthew R. Sydes	2018	1
10	The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD) Annals of Oncology ·S. Chowdhury,Wassim Abida,R Ostime Committee,Gedske Daugaard,Karim Fizazi,Somaieh Soosani,Axel Heidenreich,I Popescu,Ray McDermott,Axel S. Merseburger,J.M. Piulats Rodriguez,Brieuc Sautois,Srikala S. Sridhar,Cora N. Sternberg,Simon P. Watkins,Andrew D. Simmons,Surekha D Shetty,배원호,Charles J. Ryan,Howard I. Scher	2017	2
11	Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476) Annals of Oncology ·Nicholas D. James,Johann S. de Bono,Melissa Spears,Noel W. Clarke,Malcolm D. Mason,David P. Dearnaley,A.W.S. Ritchie,Martin Russell,Clare Gilson,Robert J. Jones,Silke Gillessen,David Matheson,Sophia McKinley,Alison Birtle,S. Chowdhury,Joanna Gale,Zafar Malik,Joe M. O’Sullivan,Mahesh Parmar,Matthew R. Sydes	2017	7
12	King’s Health Partners’ Prostate Cancer Biobank (KHP PCaBB) BMC Cancer ·高志伟,Wout Devlies,Aida Santaolalla,Fidelma Cahill,Gincy George,Deborah Enting,Sarah Rudman,Paul Cathcart,Ben Challacombe,Prokar Dasgupta,Christine Galustian,Ashish Chandra,S. Chowdhury,Cheryl Gillett,Mieke Van Hemelrijck	2017	11
13	Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC) Annals of Oncology ·Andrea Necchi,Guru Sonpavde,Salvatore Lo Vullo,Aristotelis Bamias,Simon J. Crabb,Lauren C. Harshman,Joaquim Bellmunt,Ugo De Giorgi,Cora N. Sternberg,Sylvain Ladoire,Kamrul H Foysal,Elaine Yu,S. Chowdhury,Günter Niegisch,S. Srinivas,Ulka N. Vaishampayan,Sumanta K. Pal,Jonathan E. Rosenberg,Luigi Mariani,Matt D. Galsky	2016	1
14	Efficacy of cabazitaxel, abiraterone, enzalutamide and docetaxel sequence in men with metastatic castration-resistant prostate cancer (mCRPC) in real life practice: The multinational, retrospective, observational CATS study Annals of Oncology ·Antoine Angelergues,Alison Birtle,Shafira Putri Dewanti,Orazio Caffo,Sylvestre Le Moulec,Michael Krainer,Aline Guillot,Ali Hasbini,Gedske Daugaard,S. Chowdhury,D. Spaëth,Philippe Beuzeboc,S. Taneja,Aude Fléchon,Jérôme Alexandre,Frank Priou,Nicolas Delanoy,Y Chen,Hugo Swenson,Stéphane Oudard	2016	2
15	A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK) Annals of Oncology ·Thomas Powles,Janet E. Brown,James Larkin,Robert J. Jones,Christy Ralph,Robert D. Hawkins,S. Chowdhury,Ekaterini Boleti,Sumner Thompson,Kate Fife,Andrew Webb,Simon J. Crabb,T. Geldart,Robert Hill,Joanna Dunlop,Peter E. Hall,Duncan B. McLaren,Charlotte Ackerman,Luis Beltrán,Paul Nathan	2016	16
16	Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial Annals of Oncology ·T.B. Powles,Bernard Escudier,Paul de Souza,S. Chowdhury,David Pook,Ulrika Harmenberg,Naveen S. Basappa,Daniel M. Geynisman,Jaime R. Merchan,Bruce G. Redman,Christopher W. Ryan,Luís Gustavo Caldas de Andrade,Thai H. Ho,Parminder Singh,Julie C. Lougheed,Manali I. Patel,Jennifer J. Knox,Robert J. Motzer,Toni K. Choueiri	2016	1
17	Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials Annals of Oncology ·S. Chowdhury,Neal D. Shore,Fred Saad,Celestia S. Higano,Karim Fizazi,Peter Iversen,K. Miller,Axel Heidenreich,Takeshi Ueda,Yang Kai-zhong,D. Phung,Andrew Krivoshik,J R Knowles,Kaijie Wu,Bertrand Tombal	2016	2
18	A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer Annals of Oncology ·Thomas Powles,Irfan Kayani,Kevin Sharpe,Louise Lim,John Peters,Grant D. Stewart,Daniel M. Berney,Anju Sahdev,S. Chowdhury,Ekaterini Boleti,Jonathan Shamash,Andrew R. Reynolds,Robert J. Jones,Christian U. Blank,John B.A.G. Haanen,Axel Bex	2013	37
19	The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer Annals of Oncology ·Thomas Powles,Irfan Kayani,Christian U. Blank,S. Chowdhury,Simon Horenblas,John Peters,Jonathan Shamash,Naveed Sarwar,Ortiz Armenta A,A. Sadev,Joachim Quetz,Daniel M. Berney,Luis Beltrán,John B.A.G. Haanen,Axel Bex	2011	66
20	New approaches to the systemic treatment of melanoma Cancer Treatment Reviews ·S. Chowdhury,Matthew Vaughan,Martin Gore	1999	21

About S. Chowdhury

S. Chowdhury is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 58 papers that have together received 951 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (34 papers), Radiopharmaceutical Chemistry and Applications (20 papers), Cancer, Lipids, and Metabolism (12 papers), Renal cell carcinoma treatment (11 papers), Cancer Treatment and Pharmacology (8 papers), Renal and related cancers (6 papers), PARP inhibition in cancer therapy (6 papers) and Cancer Genomics and Diagnostics (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (699 citations), Cancer Research (291 citations) and Radiology, Nuclear Medicine and Imaging (242 citations). S. Chowdhury has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Johann S. de Bono, Gerhardt Attard, Roberta Ferraldeschi, Aurelius Omlin, Andrea Zivi, Alejo Rodríguez‐Vida, David Lorente, Diletta Bianchini, Carmel Pezaro and Alexander Fuchs. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, British Journal of Cancer, JNCI Journal of the National Cancer Institute and Targeted Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact